Your browser doesn't support javascript.
loading
Diversity of oncopharmacogenetic profile within Spanish population.
Ferrer Bolufer, Irene; Galiana Vallés, Ximo; Izquierdo Álvarez, Silvia; Serrano Mira, Ana; Guzmán Luján, Carola; Safont Aguilera, María José; González Tarancón, Ricardo; Bolaños Naranjo, Matilde; Carrasco Salas, Pilar; Santamaría González, María; Rodríguez-López, Raquel.
Afiliación
  • Ferrer Bolufer I; Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia.
  • Galiana Vallés X; Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia.
  • Izquierdo Álvarez S; Genetics Laboratory, Clinical Biochemistry Service, Miguel Servet University Hospital, Zaragoza.
  • Serrano Mira A; Human Genetics Unit, Clinical Analysis Service, Juan Ramón Jiménez Hospital, Huelva.
  • Guzmán Luján C; Genetics Laboratory, Clinical Analysis Service, General Hospital Consortium of Valencia, Valencia.
  • Safont Aguilera MJ; Oncology Service, General Hospital Consortium of Valencia, Valencia.
  • González Tarancón R; Genetics Laboratory, Clinical Biochemistry Service, Miguel Servet University Hospital, Zaragoza.
  • Bolaños Naranjo M; Medical Oncology Service, Juan Ramón Jiménez Hospital, Huelva.
  • Carrasco Salas P; Human Genetics Unit, Clinical Analysis Service, Juan Ramón Jiménez Hospital, Huelva.
  • Santamaría González M; Genetics Commission, Spanish Society of Laboratory Medicine, Barcelona, Spain.
  • Rodríguez-López R; Genetics Laboratory, Clinical Biochemistry Service, Miguel Servet University Hospital, Zaragoza.
Pharmacogenet Genomics ; 34(5): 166-169, 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38488402
ABSTRACT
Consensus guidelines for genotype-guided fluoropyrimidine dosing based on variation in the dihydropyrimidine dehydrogenase (DPYD) gene before treatment have been firmly established. The prior pharmacogenetic report avoids the serious toxicity that inevitably occurred in a non-negligible percentage of the treated patients. The precise description of the allelic distribution of the variants of interest in our reference populations is information of great interest for the management of the prescription of these antineoplastic drugs. We characterized the allelic distribution of the UGT1A1*28 variant (rs3064744), as well as the DPYD*2A (rs3918290) variant, c.1679T>G (rs55886062), c.2846A>T (rs67376798) and c.1129-5923C>G (rs75017182; HapB3) in series of 5251 patients who are going to receive treatment with irinotecan and fluoropyrimidines, representative of Valencian, Aragonese and Western Andalusian populations.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glucuronosiltransferasa / Dihidrouracilo Deshidrogenasa (NADP) Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Pharmacogenet Genomics Asunto de la revista: FARMACOLOGIA / GENETICA MEDICA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Glucuronosiltransferasa / Dihidrouracilo Deshidrogenasa (NADP) Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Pharmacogenet Genomics Asunto de la revista: FARMACOLOGIA / GENETICA MEDICA Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos